Home >> Signaling Pathways >> Tyrosine Kinase >> RET

RET

RET (REarranged during Transfection) is a receptor protein tyrosine kinase, which activates multiple signal transduction pathways. RET protein is composed of three domains: an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic tyrosine kinase domain. The RET receptor tyrosine kinase (RTK) regulates key aspects of cellular proliferation and survival by regulating the activity of the mitogen- activated protein kinase (MAPK) and PI3K/Akt signaling pathways. RET also interacts directly with other kinases such as the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) and the focal adhesion kinase (FAK). Furthermore, BRAF and p38MAPK are downstream targets of RET. Kinase inhibitors that simultaneously inhibit RET and its downstream targets.

RET tyrosine kinase receptor presents an attractive therapeutic target for the treatment of certain cancer subsets. Deregulated RET activity has been identified as a causative factor in the development, progression and response to therapy of thyroid carcinoma. Elevated RET expression has been associated with the development of endocrine resistance in human breast cancer.

Targets for  RET

Products for  RET

  1. Cat.No. Product Name Information
  2. GC32797 AD80 AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity. AD80  Chemical Structure
  3. GC16391 Amuvatinib (MP-470, HPK 56) A multi-targeted RTK inhibitor Amuvatinib (MP-470, HPK 56)  Chemical Structure
  4. GC33362 Amuvatinib hydrochloride (MP470 hydrochloride) Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. Amuvatinib hydrochloride (MP470 hydrochloride)  Chemical Structure
  5. GC14292 Apatinib Mesylate

    Apatinib blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization.

    Apatinib Mesylate  Chemical Structure
  6. GC10914 AST 487 A multi-kinase inhibitor AST 487  Chemical Structure
  7. GC19062 BBT594 BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment. BBT594  Chemical Structure
  8. GC34509 BT-13 BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat. BT-13  Chemical Structure
  9. GC65354 Enbezotinib Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer. Enbezotinib  Chemical Structure
  10. GC18492 GSK3179106 A RET kinase inhibitor GSK3179106  Chemical Structure
  11. GC34159 Ilorasertib (ABT-348) Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib (ABT-348)  Chemical Structure
  12. GC38519 Ilorasertib hydrochloride Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib hydrochloride  Chemical Structure
  13. GC15454 Lenvatinib (E7080) Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. Lenvatinib (E7080)  Chemical Structure
  14. GC36438 Lenvatinib mesylate An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate  Chemical Structure
  15. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide  Chemical Structure
  16. GC31780 Pralsetinib (Blu667) Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (Blu667) (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively. Pralsetinib (Blu667)  Chemical Structure
  17. GC37047 Pz-1 Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases. Pz-1  Chemical Structure
  18. GC10111 Regorafenib A multi-kinase inhibitor Regorafenib  Chemical Structure
  19. GC14606 Regorafenib hydrochloride A multi-kinase inhibitor Regorafenib hydrochloride  Chemical Structure
  20. GC14534 Regorafenib monohydrate A multi-kinase inhibitor Regorafenib monohydrate  Chemical Structure
  21. GC67917 RET-IN-7 RET-IN-7  Chemical Structure
  22. GC33192 Selpercatinib A RET kinase inhibitor Selpercatinib  Chemical Structure
  23. GC34809 SPP-86 SPP-86 is a potent and selective cell permeable inhibitor of RET tyrosine kinase, with an IC50 of 8 nM. SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells. SPP-86  Chemical Structure
  24. GC10035 TG101209 An inhibitor of JAK2, FLT3, RET, and JAK3 TG101209  Chemical Structure
  25. GC68396 Vepafestinib Vepafestinib  Chemical Structure
  26. GC37933 WHI-P180 hydrochloride WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 hydrochloride  Chemical Structure
  27. GC64340 Zeteletinib Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity. Zeteletinib  Chemical Structure

26 Item(s)

per page

Set Descending Direction